News | August 13, 2023
WuXi XDC and Boostimmune sign MoU for integrated services
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
